Segment Information and Concentrations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Revenues	$ 2,864,900	$ 2,508,600	$ 8,623,500	$ 7,245,100
Income (Loss) from Operations			405,400
Depreciation and Amortization and Impairment			581,800	126,700
Benchtop Laboratory Equipment
Revenues	2,434,600	2,365,700	7,465,700	6,803,300
Foreign Sales	783,600	942,200	2,814,700	2,724,800
Income (Loss) from Operations	247,300	394,700	1,107,000	1,347,100
Assets	10,231,100	5,979,400	10,231,100	5,979,400
Long-lived Asset Expenditures	16,500	18,600	83,100	54,100
Depreciation and Amortization and Impairment	24,600	30,000	71,200	79,700
Bioprocessing Systems
Revenues	430,300	142,900	1,157,800	441,800
Foreign Sales	269,700	102,600	791,200	395,000
Income (Loss) from Operations	(1,651,700)	(1,323,900)	(5,091,300)	(2,598,000)
Assets	10,024,261	1,281,200	10,024,261	1,281,200
Long-lived Asset Expenditures	158,000	92,100	321,300	170,800
Depreciation and Amortization and Impairment	229,900	16,700	510,600	46,500
Consolidated
Revenues	2,864,900	2,508,600	8,623,500	7,245,100
Foreign Sales	1,053,300	1,044,800	3,605,900	3,119,800
Income (Loss) from Operations	(1,742,300)	(1,858,800)	(5,111,500)	(2,298,900)
Assets	30,526,800	13,900,300	30,526,800	13,900,300
Long-lived Asset Expenditures	174,500	110,700	404,400	224,900
Depreciation and Amortization and Impairment	254,500	46,700	581,800	126,700
Corporate and Other [Member]
Revenues	0	0	0	0
Foreign Sales	0	0	0	0
Income (Loss) from Operations	(337,900)	(929,600)	(1,127,200)	(1,048,000)
Assets	10,271,439	6,639,700	10,271,439	6,639,700
Long-lived Asset Expenditures	0	0	0	0
Depreciation and Amortization and Impairment	$ 0	$ 0	$ 0	$ 500